针刺治疗颈动脉粥样硬化斑块的临床研究

注册号:

Registration number:

ITMCTR2100004608

最近更新日期:

Date of Last Refreshed on:

2021-01-04

注册时间:

Date of Registration:

2021-01-04

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺治疗颈动脉粥样硬化斑块的临床研究

Public title:

Clinical study on acupuncture treatment of carotid atherosclerotic plaque

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗颈动脉粥样硬化斑块穴位优化的临床研究

Scientific title:

Clinical study on acupuncture treatment of carotid atherosclerotic plaque acupoint optimization

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100041762 ; ChiMCTR2100004608

申请注册联系人:

黄熙畅

研究负责人:

黄熙畅

Applicant:

Huang Xichang

Study leader:

Huang Xichang

申请注册联系人电话:

Applicant telephone:

+86 15626101472

研究负责人电话:

Study leader's telephone:

+86 15626101472

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

584238223@qq.com

研究负责人电子邮件:

Study leader's E-mail:

584238223@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国广东省广州市白云区三元里机场路12号

研究负责人通讯地址:

中国广东省广州市白云区三元里机场路12号

Applicant address:

12, Airport Road, Sanyuanli, Baiyun District, Guangzhou, Guangdong, China

Study leader's address:

12 Airport Road, Sanyuanli, Baiyun District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学

Applicant's institution:

Guangzhou University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

Y2020-195-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/9/28 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Li Xiyan

伦理委员会联系地址:

广东省广州市越秀区大德路111号广东省中医院广东省中医院伦理委员会

Contact Address of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine, 111 Dade Road, Yuexiu District, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Provincial Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号

Primary sponsor's address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

具体地址:

越秀区大德路111号

Institution
hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine

Address:

111 Dade Road, Yuexiu District

经费或物资来源:

研究生科研经费

Source(s) of funding:

Graduate research funding

研究疾病:

动脉粥样硬化

研究疾病代码:

Target disease:

Atherosclerosis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

优化针刺治疗颈动脉粥样硬化斑块的穴位方案。

Objectives of Study:

Optimize acupuncture points for the treatment of carotid atherosclerotic plaque.

药物成份或治疗方案详述:

治疗方案: 试验组:人迎组 取穴:人迎(真针刺)内关、阳陵泉、百会、印堂(假针刺) 穴位定位参照2006年中华人民共和国国家标准(GB/T12346-2006)《腧穴名称与定位》。 操作流程:患者体位采取仰卧位。针灸师用75%的酒精对自己双手及受试者双侧的穴位处进行消毒后,将在双侧的穴位处覆盖套叠泡沫胶垫(1*1*1cm3)。人迎穴采用0.25×0.25mm的一次性无菌针灸针,穿过中空管,透过泡沫胶垫刺入穴位。针刺深度为0.5-1.0cm,具体以穴位部位、体型胖瘦而定。进针后,以受试者觉局部有酸麻胀重的得气感即止。其余穴位(内关、阳陵泉、百会、印堂)采用0.25×0.25mm的一次性无菌钝头(无法刺破皮肤)针灸针穿过中空管,穿过泡沫垫触碰受试者皮肤,钝头针无法刺破皮肤,仅在局部产生按压针身时对皮肤触碰产生的刺痛感,与正常针刺进针时具有相似的痛感。留针时间为30分钟。 对照组:针刺组 取穴:人迎、内关、阳陵泉、百会、印堂(真针刺) 穴位定位参照2006年中华人民共和国国家标准(GB/T12346-2006)《腧穴名称与定位》。 操作流程:患者体位采取仰卧位。针灸师用75%的酒精对自己双手及受试者双侧的穴位处进行消毒后,将在双侧的穴位处覆盖套叠泡沫胶垫(1*1*1cm3)。所有穴位(人迎、内关、阳陵泉、百会、印堂)均采用0.25×0.25mm的一次性无菌针灸针,穿过中空管,透过泡沫胶垫刺入穴位。针刺深度为0.5-1.0cm,具体以穴位部位、体型胖瘦而定。进针后,以受试者觉局部有酸麻胀重的得气感即止。留针时间为30分钟。

Description for medicine or protocol of treatment in detail:

treatment plan: Test group: Renying group Acupoint selection: Renying (real acupuncture) Neiguan, Yanglingquan, Baihui, Yintang (fake acupuncture) The acupoint location refers to the 2006 National Standard of the People's Republic of China (GB/T12346-2006) "Acupoint Name and Location". Operation process: The patient's position is supine. After the acupuncturist disinfects his hands and the acupoints on both sides of the subject with 75% alcohol, he will cover the acupuncture points on both sides with invading foam pads (1*1*1cm3). Renying acupuncture point uses a 0.25×0.25mm disposable sterile acupuncture needle, which passes through the hollow tube and penetrates into the acupuncture point through the foam rubber pad. The depth of acupuncture is 0.5-1.0cm, depending on the acupoint location and body size. After the needle was inserted, the subject felt sore and numb and swollen locally. For the remaining acupuncture points (Neiguan, Yanglingquan, Baihui, Yintang), a 0.25×0.25mm disposable sterile blunt tip (not able to pierce the skin) acupuncture needles pass through the hollow tube and touch the subject through the foam pad On the skin, a blunt needle cannot pierce the skin, but only locally produces a tingling sensation when the needle is pressed against the skin, which is similar to the pain when a normal needle is inserted into the needle. Needle retention time is 30 minutes. Control group: acupuncture group Acupoint selection: Renying, Neiguan, Yanglingquan, Baihui, Yintang (real acupuncture) The acupoint location refers to the 2006 National Standard of the People's Republic of China (GB/T12346-2006) "Acupoint Name and Location". Operation process: The patient's position is supine. After the acupuncturist disinfects his hands and the acupoints on both sides of the subject with 75% alcohol, he will cover the acupuncture points on both sides with invading foam pads (1*1*1cm3). All acupuncture points (Renying, Neiguan, Yanglingquan, Baihui, Yintang) use disposable sterile acupuncture needles of 0.25×0.25mm, which are inserted into the acupuncture points through the hollow tube and through the foam rubber pad. The depth of acupuncture is 0.5-1.0cm, depending on the acupoint location and body size. After the injection, the subject felt sore, numb, swollen and swollen locally. Needle retention time is 30 minutes.

纳入标准:

(1)年龄在45-70周岁之间; (2)符合动脉粥样硬化斑块的诊断标准; (3)颈动脉内中膜增厚,为稳定性扁平斑块,无不稳定型活动斑块,双侧动脉斑块总数≤5个; (4)颈动脉狭窄<50%者; (5)低密度脂蛋白胆固醇水平在2.59mmol/L-8.0mmol/L之间,甘油三脂水平在1.7mmol/L-10.0mmol/L之间; (6)近2周未使用与改善动脉粥样硬化有关的药物,如治疗高血压、心力衰竭、高血脂、糖尿病等药物; (7)自愿参加研究,并能配合安排及理解研究内容者;

Inclusion criteria

(1) Aged between 45-70 years; (2) Meet the diagnostic criteria for atherosclerotic plaque; (3) Carotid artery intima-media is thickened, stable flat plaque, no unstable active plaque, total number of bilateral arterial plaques <= 5; (4) Carotid artery stenosis < 50%; (5) The low-density lipoprotein cholesterol level is between 2.59mmol/L-8.0mmol/L, and the triglyceride level is between 1.7mmol/L-10.0mmol/L; (6) No drugs related to improving atherosclerosis have been used in the past 2 weeks, such as drugs for the treatment of hypertension, heart failure, hyperlipidemia, diabetes, etc.; (7) Those who voluntarily participate in the research and can cooperate with the arrangement and understand the research content.

排除标准:

具有下列任何一项标准的患者将被排除在外: (1)年龄≥60岁、肥胖、糖尿病、高血压、低HDL-C、吸烟六个危险因素合并4个以上; (2)曾患脑血管意外、短暂性大脑缺血发作、严重创伤或行重大手术者; (3)有心脏、肝脏、肾脏或造血系统有关的严重疾病者; (4)有认知障碍等精神类疾病者; (5)有皮肤病和出血性疾病者; (6)害怕针灸者;在研究期间怀孕,母乳喂养或计划怀孕的人; (7)参加其他试验者。

Exclusion criteria:

Patients with any of the following criteria will be excluded: (1) The six risk factors of age >= 60 years, obesity, diabetes, high blood pressure, low HDL-C, and smoking are combined with more than 4; (2) Those who have suffered from cerebrovascular accident, transient cerebral ischemic attack, severe trauma or major surgery; (3) Those with serious diseases related to the heart, liver, kidney or hematopoietic system; (4) People with mental illness such as cognitive impairment; (5) People with skin diseases and bleeding diseases; (6) Those who are afraid of acupuncture; those who become pregnant, breastfeeding or planning to become pregnant during the study period; (7) Participants in other trials.

研究实施时间:

Study execute time:

From 2021-01-11

To      2022-04-11

征募观察对象时间:

Recruiting time:

From 2021-01-15

To      2022-01-15

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

人迎、内关、阳陵泉、百会、印堂(真针刺)

干预措施代码:

Intervention:

Renying, Neiguan, Yanglingquan, Baihui, Yintang acupuncture

Intervention code:

组别:

试验组

样本量:

30

Group:

experimental group

Sample size:

干预措施:

人迎(真针刺)内关、阳陵泉、百会、印堂(假针刺)

干预措施代码:

Intervention:

Renying acupuncture

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省中医院

单位级别:

三级甲等

Institution/hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

斑块体积

指标类型:

主要指标

Outcome:

Plaque volume

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动脉收缩开始和收缩结束的脉搏波速度

指标类型:

次要指标

Outcome:

BS、ES

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

斑块积分

指标类型:

主要指标

Outcome:

Crouse Plaque score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

灰阶中位值

指标类型:

主要指标

Outcome:

Gray Scale Median

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

内中膜厚度

指标类型:

主要指标

Outcome:

Intima Media Thickness

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 45
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

所有满足纳入条件的受试者在配合负责招募的研究助理完成信息登记及筛查后,将统一按纳入顺序交由负责分配入组的研究者进行随机分组。两组按照1:1的比例进行随机分配。

Randomization Procedure (please state who generates the random number sequence and by what method):

All subjects who meet the enrollment conditions will be assigned to the researcher in charge of enrollment for random grouping in accordance with the order of inclusion after completing the information registration and screening with the research assistant responsible for recruitment.

盲法:

对受试者施盲

Blinding:

Blind method for subjects.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

所有数据将上传至中国临床科研注册中心的ResMan Research Manager数据库内。为获得完整试验、数据及统计程序的公众,需要在全部研究结束,论文发表后,经过研究主要负责人的同意批准后获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

All data will be uploaded to the ResMan Research Manager database of the China Clinical Research Registry. In order to obtain complete trials, data and statistical procedures for the public, it is nec

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有受试者的数据均由3名负责数据汇总及整理的研究人员负责,由2名研究人员分别对所有数据进行整理和汇总,并进行双盲独立录入。由第3名研究人员负责数据的核对和矫正。数据采集和录入的相关人员,均不参与人员分配、治疗等过程,对受试者分组及治疗情况不知情。所有数据均以图片、纸质版、电子表格的方式进行保存,数据管理由临床试验管理公众平台的ResMan Research Manager负责。本研究还将成立数据监测委员会,由广东省中医院针灸研究团队具有专业临床研究经验的专家负责,专家将会定期对数据采集、汇总、储存进行监督。委员会所有负责人员均与本研究基金发起人没有任何利益冲突。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data of all subjects are handled by three researchers who are responsible for data collection and sorting, and all data will be sorted and summarized by 2 researchers, and double-blind independent entry is performed. The third researcher is responsible for data verification and correction. The personnel involved in data collection and input are not involved in the process of personnel allocation and treatment, and are unaware of the grouping and treatment of subjects. All data are saved in the form of pictures, paper versions, and electronic forms, and data management is in charge of the ResMan Research Manager of the clinical trial management public platform. In this study, a data monitoring committee will be established, which will be in charge of experts from the acupuncture research team of Guangdong Provincial Hospital of Traditional Chinese Medicine who have professional clinical research experience. The experts will regularly supervise data collection, aggregation, and storage. All persons in charge of the committee have no conflicts of interest with the sponsors of this research fund.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统